D. Daniel

发表

Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer

D. Hanahan, Z. Cao, D. Daniel, 2002, BMC Cancer.

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

A. Yang, R. Offringa, D. Lawrence, 2011, Cancer cell.

Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Phosphopantetheinyl Transferases.

Scott A Lesley, Badry Bursulaya, Susan E. Cellitti, 2015, Bioconjugate chemistry.

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

D. Fabbro, W. Jahnke, G. Rummel, 2015, ACS medicinal chemistry letters.

Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

M. P. Dillon, R. Grotzfeld, Edward G. Lorenzana, 2019, ACS medicinal chemistry letters.

Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma

A. Ashkenazi, S. Ross, K. Wagner, 2007 .

Immune Enhancement of Skin Carcinogenesis by CD4 (cid:2) T Cells

D. Hanahan, L. Coussens, D. Daniel, 2003 .

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

Vivien W. Chan, L. Coussens, H. Rugo, 2014, Cancer cell.

CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.

D. Hanahan, E. Giraudo, M. Inoue, 2005, Cancer research.

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

Christina S. Leslie, Manu Setty, Eric C. Holland, 2013, Nature Medicine.

Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes

R. Sposto, R. Seeger, Jianping Sun, 2018, International journal of cancer.

TWEAK Attenuates the Transition from Innate to Adaptive Immunity

D. Lawrence, D. Danilenko, H. Maecker, 2005, Cell.

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells

L. Coussens, M. Bissell, N. Pryer, 2013, Oncoimmunology.

New Agents With Potential for Radiation Enhancement Daniel D. Von HqiJand The San Antonio Drug Development Team

D. Daniel, 1997 .

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2021, Cancer Immunology Research.

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.

D. Lawrence, A. Ashkenazi, S. Ross, 2007, Blood.

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

B. Weisburd, F. McCormick, M. Holderfield, 2014, Cancer research.

Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells

D. Hanahan, L. Coussens, D. Daniel, 2003, The Journal of experimental medicine.

Abstract 5691: Evaluation of immunomodulatory agents in classically immunologically 'cold' cancers using syngeneic mouse models of breast and ovarian cancer

D. Draper, D. Daniel, Kevin Guley, 2018, Immunology.

Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer

D. Hanahan, Z. Cao, D. Daniel, 2002, BMC Cancer.

Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer

D. Hanahan, Z. Cao, D. Daniel, 2002, BMC Cancer.